CHCHD5

Across TCGA pan-cancer cohorts, CHCHD5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CHCHD5 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CHCHD5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHCHD5 expression acts as an unfavorable survival marker.

CCRCC, HNSC, and PDAC are the cancer types where CHCHD5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.558	1.000	.003	50	view →
HNSC	DFS	Median	III,IV	0.722	0.880	.034	6	view →
PDAC	OS	Median	IV	0.381	0.951	.006	6	view →
LUAD	OS	Quartile	All	0.786	0.938	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CHCHD5–CCRCC (DFS)

Open the CCRCC breakdown →